Medical Technology Firm
Active 2007–2026. The register lists this client once for every firm that files on its behalf; all 7 of its records are shown together here.
These two figures are not added together. A client that lobbies for itself reports its own spending, while firms it retains report what they were paid. Disclosure rules ask the in-house figure to include those payments, but filings do not always do so, and a filing gives no way to tell. Each is shown as reported.
| Year | Firm | Period | Amount | Doc |
|---|---|---|---|---|
| 2026 | BIOGEN |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$880,000 | |
| 2026 | BIOGEN |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$1,060,000 | |
| 2026 | BIOGEN |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$1,460,000 | |
| 2025 | BIOGEN |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$770,000 | |
| 2025 | BIOGEN |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$990,000 | |
| 2025 | BIOGEN |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$1,380,000 | |
| 2025 | BIOGEN |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
$1,020,000 | |
| 2024 | BIOGEN |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
$700,000 | |
| 2024 | BIOGEN |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
$710,000 | |
| 2024 | BIOGEN |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
$1,670,000 |
| Firm | Filings | Amount |
|---|---|---|
| BIOGEN IN-HOUSE | 81 | $51,331,680 |
| W STRATEGIES, LLC | 35 | $1,700,000 |
| NVG, LLC | 44 | $1,600,000 |
| THORN RUN PARTNERS | 23 | $940,000 |
| CAPITOL HILL STRATEGIES, LLC | 18 | $750,000 |
| CLYBURN CONSULTING, LLC | 6 | $200,000 |
| LATHAM & WATKINS LLP | 1 | — |
| Issue | Activities |
|---|---|
| Health Issues | 181 |
| Medicare/Medicaid | 134 |
| Copyright/Patent/Trademark | 101 |
| Taxation/Internal Revenue Code | 71 |
| Trade (domestic/foreign) | 63 |
| Pharmacy | 29 |
| Medical/Disease Research/Clinical Labs | 23 |
| Budget/Appropriations | 23 |
| Manufacturing | 3 |
| Transportation | 1 |